Assertio Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St futures muted as bond yields resume climb; Walmart drops after results
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Crypto stocks surge as Bitcoin short squeeze hits record $2.7B
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Assertio Therapeutics (ASRT) Tops Q2 EPS by 20c
August 8, 2022 7:03 AM EDTAssertio Therapeutics (NASDAQ: ASRT) reported Q2 EPS of $0.28, $0.20 better than the analyst estimate of $0.08. Revenue for the quarter came in at $35.4 million versus the consensus estimate of $31.63 million.
For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.
... More